Zytiga (Abiraterone) 500 mg – Hormonal Therapy for Prostate Cancer Zytiga (Abiraterone acetate)

Zytiga 500 mg is an advanced hormonal therapy used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is one of the key modern treatments that targets the hormonal source driving tumor growth.

What is Zytiga?

Zytiga works by inhibiting an important enzyme called CYP17, which is responsible for the production of testosterone in the body.

Since prostate cancer cells rely heavily on male hormones to grow, reducing testosterone levels helps to:

• Slow down tumor growth
• Reduce cancer spread
• Improve disease control in advanced stages

In simple terms:
It reduces the hormonal “fuel” that feeds cancer growth.

Indications

Zytiga (Abiraterone) is used in:

• Metastatic prostate cancer
• Cases resistant to standard hormonal therapy
• Usually combined with androgen deprivation therapy (ADT)
• Administered with Prednisone as part of the treatment protocol

Dosage and Administration

• Standard dose: 1000 mg daily (often using 500 mg tablets depending on availability)
• Taken on an empty stomach (2 hours before or after food)
• Must be taken together with Prednisone as prescribed
• Daily adherence is essential for treatment effectiveness

Common Side Effects

May include:

• Fluid retention or swelling
• High blood pressure
• Fatigue
• Low potassium levels
• Liver function changes
• Headache or dizziness

Regular medical monitoring is essential during treatment.

Monitoring During Treatment

Patients on Zytiga (Abiraterone) require:

• Liver function tests
• Blood pressure monitoring
• Electrolyte (potassium) checks
• Regular assessment of tumor response

Availability in Egypt

 Zytiga  is available in specialized oncology centers and major pharmacies in Egypt, but:

• It is a high-cost medication
• Requires close supervision by an oncology specialist
• Used within structured hormonal therapy protocols

Importance of Zytiga (Abiraterone)

Zytiga is a major advancement because it:

• Targets hormone production inside the body
• Slows disease progression in advanced cases
• Improves long-term disease control
• Is widely included in international prostate cancer guidelines

Zytiga 500 mg is a powerful hormonal therapy for advanced prostate cancer that works by reducing the hormones that fuel tumor growth, helping to slow disease progression and improve patient outcomes.

Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified oncology specialist.